OrthoPediatrics Corp. (KIDS)
OrthoPediatrics (KIDS) Reports Q4 Loss, Misses Revenue Estimates
OrthoPediatrics (KIDS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago.
OrthoPediatrics Corp. (KIDS) Q3 2024 Earnings Call Transcript
OrthoPediatrics Corp. (NASDAQ:KIDS ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Trip Taylor - Gilmartin Group David Bailey - President & Chief Executive Officer Fred Hite - Chief Financial Officer & Chief Operating Officer Conference Call Participants Matt O'Brien - Piper Sandler Joseph Conway - Needham & Company Operator Good morning and welcome to OrthoPediatrics Corporation's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Compared to Estimates, OrthoPediatrics (KIDS) Q3 Earnings: A Look at Key Metrics
The headline numbers for OrthoPediatrics (KIDS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue Estimates
OrthoPediatrics (KIDS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.13 per share a year ago.
What Makes OrthoPediatrics (KIDS) a New Strong Buy Stock
OrthoPediatrics (KIDS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down -15.65% in 4 Weeks, Here's Why You Should You Buy the Dip in OrthoPediatrics (KIDS)
OrthoPediatrics (KIDS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bears are Losing Control Over OrthoPediatrics (KIDS), Here's Why It's a 'Buy' Now
OrthoPediatrics (KIDS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Does OrthoPediatrics (KIDS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in OrthoPediatrics (KIDS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
KIDS Stock Gains From Its New Enabling Technologies Division Launch
OrthoPediatrics recently launched its Enabling Technologies division, set to generate sustainable revenue growth and gain access to new markets and specialties beyond orthopedics.
Wall Street Analysts Predict a 31.2% Upside in OrthoPediatrics (KIDS): Here's What You Should Know
The consensus price target hints at a 31.2% upside potential for OrthoPediatrics (KIDS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OrthoPediatrics Corp. (KIDS) Q2 2024 Earnings Call Transcript
OrthoPediatrics Corp. (NASDAQ:KIDS ) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants Trip Taylor - Gilmartin Group David Bailey - President & Chief Executive Officer Fred Hite - Chief Financial Officer & Chief Operating Officer Conference Call Participants Rick Wise - Stifel Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Mike Matson - Needham Dave Turkaly - Citizens JMP Ravi Misra - Truist Operator Good morning, and thank you for standing-by. Welcome to the Second Quarter 2024 OrthoPediatrics Earnings Conference Call.
OrthoPediatrics (KIDS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for OrthoPediatrics (KIDS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
